Cited by 69Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease‐related pathology

Thal, D. R., Schultz, C., Botez, G., Del Tredici, K., Mrak, R. E., Griffin, W. S. T., Wiestler, O. D., Braak, H. +1 more·2005·Neuropathology and Applied Neurobiology

Abstract

Argyrophilic grain disease (AGD) constitutes a neurodegenerative disorder that occurs in the brains of the elderly and affects 5% of all patients with dementia. Tau protein-containing lesions known as argyrophilic grains and located predominantly in limbic regions of the brain characterize this disease. Dementia is encountered in only a subset of cases that display the morphological pattern of AGD. The aim of this study is to determine the role of concurrent Alzheimer's disease (AD)-related pathology for the development of dementia in AGD patients. A total of 204 post-mortem brains from 30 demented and 49 nondemented AGD patients, 39 AD patients, and from 86 nondemented controls without AGD were staged for AD-related neurofibrillary tangles (NFTs) as well as amyloid beta-protein (Abeta) deposition. To identify differences in AD-related pathology between demented and nondemented AGD cases, and to differentiate the pattern of AD-related changes in demented and nondemented AGD cases from that seen in AD and nondemented controls, we statistically compared the stages of Abeta and NFT distribution among these groups. Using a logistic regression model, we showed that AGD has a significant effect on the development of dementia beyond that attributable to AD-related pathology (P < 0.005). Demented AGD cases showed lower stages of AD-related pathology than did pure AD cases but higher stages than nondemented AGD patients. AGD associated dementia was seen in the presence of NFT (Braak)-stages II-IV and Abeta-phases 2-3, whereas those stages were not associated with dementia in the absence of AGD. In conclusion, AGD is a clinically relevant neurodegenerative entity that significantly contributes to the development of dementia by lowering the threshold for cognitive deficits in the presence of moderate amounts of AD-related pathology.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2990.2005.00635.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Argyrophilic grain disease is more frequently observed in Alzheimer's disease than the general population and lowers the pathological threshold for clinical dementia.

    “Argyrophilic grain disease is not only more frequently observed in Alzheimer’s disease than the general population, but it also lowers the pathological threshold for the presentation of clinical dementia [140].”

    From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [140]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Thal, D. R., Schultz, C., Botez, G., Del Tredici, K., Mrak, R. E., Griffin, W. S. T., Wiestler, O. D., Braak, H., & Ghebremedhin, E.
Affiliations
  • University of Bonn (DE)
  • Goethe University Frankfurt (DE)
  • University of Arkansas for Medical Sciences (US)
Corresponding author
Thal, D. R.
Venue
Neuropathology and Applied Neurobiology
Publisher
Wiley
Published
2005-01-24
Volume
31
Issue
3
Pages
270-279
ISSN
  • 0305-1846 (ISSN-L)
  • 1365-2990
OpenAlex
W1990107252
Cited by
69
References
6
Citations by year
2026: 1 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 2 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 4 · 2013: 6 · 2012: 4
FWCI
2.41
Type
journal article
Language
en
Open access
closed
Locations
  • Neuropathology and Applied Neurobiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft
  • National Institute on Aging (AG 12411, P01AG012411)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
argyrophilic grain disease, dementia, Alzheimer's disease, neurofibrillary tangles, amyloid-beta deposition, Braak staging, argyrophilic grains, tau pathology, limbic system, postmortem brain, neurodegeneration
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Inclusion Bodies, Female, Humans, Male, Middle Aged, Logistic Models, Amyloid beta-Peptides, Neurofibrillary Tangles, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review